Two respiratory syncytial virus (RSV) vaccines, RSVPreF3+AS01 and RSVpreF, were highly effective at preventing hospital admissions and death among older adults during the 2023 to 2024 season. These ...

The M72/AS01 TB vaccine was safe for virologically suppressed adults with HIV, with no severe vaccine-related AEs reported.

Adults hospitalized with CAP face high mortality rates, particularly those with unsuppressed HIV and tuberculosis.

An MF59-adjuvanted, higher-dose influenza vaccine improves immune responses in older adults compared with standard egg-based options.

People with HIV experience a significantly greater increase in multimorbidity following COVID-19 diagnosis compared with those without HIV.

Meningitis incidence and mortality declined significantly in the Western Pacific Region from 1990 to 2023 following expanded vaccination initiatives.

Adults with pneumococcal meningitis of hematogenous origin face a significantly higher 30-day mortality rate than those with other sources.

Extensive testing and quarantine measures following the fatal pneumonia of a Siberian laboratory worker have yielded no evidence of pneumonic plague transmission or dangerous pathogens among close ...

Adults with HIV aged 60 years and older are more likely to report favorable quality of life (QOL) following a switch in antiretroviral therapy (ART) than adults younger than 60 ye ...

Topline phase 3 OPUS-1 data show VAX-31 met coprimary immunogenicity endpoints, demonstrating noninferiority and superiority for key pneumococcal serotypes.